MedTrace Logo

A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes

NCT04902573 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 147

Last updated 2025-09-11

No results posted yet for this study

Summary

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Conditions

Interventions

OTHER

Non-interventional

As this is a non-interventional trial, only data obtained within the current routine management of asthma at outpatient respiratory centres or GP centres will be documented.

Sponsors & Collaborators

  • Gesellschaft für Therapieforschung mbH

    collaborator INDUSTRY

  • Chiesi UK

    lead INDUSTRY

Principal Investigators

  • Richard Russell, PhD, MBBS · University of Oxford

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-17
Primary Completion
2024-06-14
Completion
2024-06-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04902573 on ClinicalTrials.gov